Copertina

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Marta Pascual‐Mato, Gabriel Gárate, Vicente González‐Quintanilla, Jorge Madera‐Fernández, Beatriz Castro, María José García, Javier Crespo, Montserrat Rivero, Julio Pascual
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Gabriel Gárate, et al.
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
di: Anna de Dios, et al.
Pubblicazione: (2024)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
di: Yunzhu Tang, et al.
Pubblicazione: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
di: Irina Krikova, et al.
Pubblicazione: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
di: Tzu‐Hsuan Su, et al.
Pubblicazione: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
di: Eric A. Kaiser, et al.
Pubblicazione: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
di: Alex Harlan, et al.
Pubblicazione: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
di: David Croteau, et al.
Pubblicazione: (2026)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
di: Zoe Tasma, et al.
Pubblicazione: (2025)

Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities—A cross‐sectional study
di: Kuang‐Heng Lee, et al.
Pubblicazione: (2025)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Ann I. Scher, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
di: Andrew C. Charles, et al.
Pubblicazione: (2024)

The role of stress in the comorbidity of migraine and other chronic primary pain
di: Shi‐Jie Zhao, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Association between migraine and exclusive breastfeeding: A cross‐sectional study
di: Manav V. Vyas, et al.
Pubblicazione: (2024)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
di: Bilal Ahmed Rizvi, et al.
Pubblicazione: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
di: Delora E. Denney, et al.
Pubblicazione: (2024)

The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross‐sectional study
di: Raffaele Ornello, et al.
Pubblicazione: (2025)

The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model
di: Philip Victor Reducha, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Michael L. Garelja, et al.
Pubblicazione: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Alicia Alpuente, et al.
Pubblicazione: (2026)

Sex‐specific differences in the relationship between AHA Life's Essential 8 factors and migraine disorders: A cross‐sectional evaluation in ELSA ‐Brasil study
di: Arão Belitardo de Oliveira, et al.
Pubblicazione: (2025)

Association between migraine and cerebral white matter hyperintensities in middle‐aged and older individuals: A cross‐sectional study using the UK Biobank cohort
di: Peng‐Peng Niu, et al.
Pubblicazione: (2025)

Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis
di: Luana Miyahira Makita, et al.
Pubblicazione: (2025)

A history of abuse is associated with more severe migraine‐ and pain‐related disability: Results from the American Registry for Migraine Research
di: Meesha Trivedi, et al.
Pubblicazione: (2024)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
di: Carlyn Patterson Gentile, et al.
Pubblicazione: (2024)

Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
di: Michael L. Garelja, et al.
Pubblicazione: (2026)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Perceptions of health, cognition, and pain among middle‐aged and older adults with migraine: A population‐based cross‐sectional study examining findings from the Canadian Longitudinal Study on Aging
di: Makenna K. N. Jensen, et al.
Pubblicazione: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
di: María Clara García‐Castillo, et al.
Pubblicazione: (2026)

Afterimage duration differs for migraine with or without aura
di: Florian Rimmele, et al.
Pubblicazione: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
di: Rebecca Erwin Wells, et al.
Pubblicazione: (2024)